PTSD Treatment Approaches: PE, CPT, EMDR & Emerging Therapies

9 Million Americans, Three Evidence-Based Paths

Post-traumatic stress disorder affects approximately 9 million adults in the United States in any given year — about 3.5% of the adult population — according to the National Comorbidity Survey Replication. Veterans and first responders experience substantially higher rates: the VA estimates that 11–20% of veterans who served in Operation Iraqi Freedom or Enduring Freedom have PTSD in a given year. Despite PTSD's prevalence, fewer than half of affected individuals receive treatment, and of those who do, a significant proportion do not respond to first-line interventions. The treatment outcome gap has driven intense research into both refinements of established therapies and genuinely novel biological approaches.

Three trauma-focused psychotherapies have the strongest empirical support and are recommended as first-line treatments by the VA/DoD Clinical Practice Guidelines, the American Psychological Association, and the International Society for Traumatic Stress Studies: Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR).

Prolonged Exposure: Extinction Learning in Practice

Prolonged Exposure was developed by Edna Foa at the University of Pennsylvania based on emotional processing theory — the hypothesis that PTSD is maintained by avoidance of trauma memories and reminders, which prevents the natural emotional processing (habituation) that would otherwise diminish fear responses over time.

Standard PE involves 8–15 weekly sessions with two core components:

• Imaginal exposure: The client narrates the trauma aloud in the present tense during sessions, repeatedly revisiting the traumatic memory until distress decreases through habituation. Sessions are recorded; clients listen to the recording as homework between sessions.
• In vivo exposure: Systematic engagement with trauma reminders (people, places, situations) that the client has been avoiding. A hierarchy of avoided situations is constructed, and clients work through it progressively.

The mechanism is extinction learning — the same neurological process underlying fear conditioning but in reverse. The prefrontal cortex, through repeated non-reinforced exposure to feared stimuli, learns to inhibit the amygdala's fear response. Neuroimaging studies show that successful PE treatment is associated with increased prefrontal activation and decreased amygdala reactivity to trauma cues — the opposite of the pattern seen in untreated PTSD.

Cognitive Processing Therapy: Challenging Stuck Points

Cognitive Processing Therapy (CPT), developed by Patricia Resick, focuses on the meaning clients assign to trauma rather than the memory itself. CPT targets "stuck points" — specific beliefs about the trauma that prevent recovery — using structured cognitive restructuring techniques.

• The standard protocol runs 12 sessions, available in individual or group format.
• Clients write a detailed impact statement describing the trauma's effects on their beliefs about themselves and the world.
• The Socratic dialogue method challenges stuck points: beliefs like "It was my fault," "I am permanently damaged," or "The world is completely dangerous."
• CPT+A (the full protocol) includes a written trauma account; CPT (the cognitive-only version) omits this account for clients who struggle with written accounts — both versions show similar outcomes.

A 2015 head-to-head RCT by Resick and colleagues published in JAMA Psychiatry compared CPT, CPT+A, and written trauma accounts alone in 150 female rape survivors. CPT and CPT+A produced significantly greater PTSD symptom reductions than the written account condition, with no significant difference between the two CPT variants.

EMDR: Cochrane Evidence and Mechanism Debate

Eye Movement Desensitization and Reprocessing (EMDR), developed by Francine Shapiro in 1987, involves having clients focus on traumatic memories while simultaneously tracking the therapist's finger movements (or other bilateral stimulation — tones, taps). EMDR's evidence base is substantial, but its mechanism remains genuinely contested.

A 2013 Cochrane review (Bisson et al.) found that trauma-focused CBT (including PE and CPT) and EMDR were both significantly more effective than waitlist controls and broadly equivalent to each other. The review classified the evidence as "moderate quality" due to heterogeneity across studies. The bilateral stimulation component of EMDR — the defining feature — does not appear necessary for its effects: controlled studies removing eye movements from the protocol show equivalent outcomes, suggesting that exposure to traumatic memories in a safe context is the active ingredient regardless of the bilateral component.

Stellate Ganglion Block: Early Evidence

The stellate ganglion block (SGB) is an anesthetic injection into a nerve cluster in the neck that has been used since the 1920s for pain management. Its application to PTSD emerged from an accidental clinical observation that some patients experienced PTSD symptom relief after SGB for unrelated pain conditions. The proposed mechanism: PTSD is associated with elevated nerve growth factor (NGF) causing sympathetic nervous system sprouting into the amygdala; SGB may reset this pathway.

A 2021 randomized sham-controlled trial published in JAMA Psychiatry (Rae Olmstead et al., n=101 military personnel) found that a single SGB produced significantly greater PTSD symptom reduction at 8 weeks compared to sham injection, with a 12-point advantage on the PTSD Checklist (PCL). A 2023 replication trial supported these findings. SGB remains experimental — not yet part of clinical guidelines — and the mechanism hypotheses have not been definitively confirmed. But the evidence is sufficiently compelling that several military medical centers now offer it within research protocols.

MDMA-Assisted Therapy

MDMA-assisted therapy for PTSD generated extensive research enthusiasm following Phase 2 trial results published in Nature Medicine in 2021, showing that 67% of participants who received MDMA-assisted therapy no longer met PTSD criteria at follow-up, compared to 32% in the placebo group. MDMA is hypothesized to temporarily reduce amygdala reactivity to trauma cues while increasing feelings of trust and social connectedness — creating an optimal window for trauma processing.

The FDA declined to approve MDMA-assisted therapy in August 2024 after a Phase 3 trial (MAPP2) showed positive but less dramatic effects, and the agency raised concerns about functional unblinding (participants can tell whether they received MDMA), potential for misuse of the therapeutic relationship, and inadequate data on how to identify patients at risk of adverse effects. The sponsor (MAPS Public Benefit Corporation) committed to conducting additional trials. Research continues, and the treatment may yet receive approval under a revised protocol.